Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareBOM:530549 -2.88%76 Net Margin % is 24.67% as of Mar. 2026, which is 71% above its 10-year median of 14.40. GuruFocus rates BOM:530549 with a GF Score™ of 76/100 and a GF Value™ of ₹387.34 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 962 Drug Manufacturers companies, Shilpa Medicare ranks better than 80.98% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Shilpa Medicare's Net Income for the
three
months ended in Mar. 2026 was ₹1,078 Mil. Shilpa Medicare's Revenue for the
three
months ended in Mar. 2026 was ₹4,370 Mil. Therefore, Shilpa Medicare's net margin for the quarter that ended in Mar. 2026 was 24.67%.
The historical rank and industry rank for Shilpa Medicare's Net Margin % or its related term are showing as below:
BOM:530549'
s Net Margin % Range Over the Past 10 Years
Min: -3.12 Med: 14.4 Max: 17.37
Current: 15.82
BOM:530549's Net Margin % is ranked better than 80.98% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs BOM:530549: 15.82
Shilpa Medicare (BOM:530549) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shilpa Medicare Net Margin % Related Terms
Shilpa Medicare Net Margin % Historical Data
* Premium members only.
The historical data trend for Shilpa Medicare's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's Net Margin % distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shilpa Medicare (BOM:530549) has a Net Margin % of 24.67% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Shilpa Medicare and its competitors. This is 71% above median its historical median of 14.40. According to the industry distribution chart, Shilpa Medicare ranks #183 out of 962 companies in the Drug Manufacturers industry, placing it in the top 19%.
Is Shilpa Medicare's Net Margin % too high?
Shilpa Medicare's current Net Margin % of 24.67% is 71% above median its 10-year median of 14.40. The Drug Manufacturers industry median Net Margin % is 5.56. Shilpa Medicare's value of 24.67% is 343.7% above this industry median. Based on the distribution chart, Shilpa Medicare ranks #183 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #183 out of 962 companies for Net Margin %. This places Shilpa Medicare in the top 19% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Shilpa Medicare's value of 24.67% is 343.7% above this benchmark. While the company's 10-year median is 14.40 vs. the industry median of 5.56, Shilpa Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current Net Margin % of 24.67% is 343.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current Net Margin % is 24.67%, which is 71% above median its own 10-year median of 14.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (BOM:530549) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.34, compared to a current price of ₹619.55 — trading 59.9% above its estimated fair value. The current Net Margin % is 24.67%, which is 71% above median its 10-year median of 14.40 and 343.7% above the Drug Manufacturers industry median of 5.56. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shilpa Medicare (BOM:530549), the current Net Margin % is 24.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (BOM:530549) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹619.55 is trading 59.9% above its estimated GF Value™ of ₹387.34.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for BOM:530549:
Net Margin %: 24.67% (71% above median its 10-year median of 14.40)
GF Value™: ₹387.34 vs. price of ₹619.55 (59.9% above fair value)
Industry Position: 343.7% above the Drug Manufacturers median (#183 of 962)
No single metric tells the full story. See the BOM:530549 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for BOM:530549
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530549 has been successfully added to your 
